Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Study of CD19/CD20 Bispecific CAR-T Cells for Relapsed or Refractory B-Cell Lymphomas and CLL
NCT04007029Phase 1Active, not recruiting
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Oct 2019
- Primary completion
- Aug 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cd19 chimeric antigen receptor t-cells + cd20 chimeric antigen receptor t-cells in diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), mantle cell lymphoma (MCL) and 3 more, sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoints: Incidence of adverse events and Dose-limiting toxicities. Started Oct 2019; status: active, not recruiting.
02
Drugs
cd19 chimeric antigen receptor t-cells + cd20 chimeric antigen receptor t-cells
03
Conditions
diffuse large B-cell lymphoma (DLBCL)primary mediastinal large B-cell lymphoma (PMBCL)mantle cell lymphoma (MCL)follicular lymphoma (FL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT04007029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04007029.